Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Davaine, Jean Michel ^a,b,c   Quillard, Thibaut ^a   Brion, Régis ^a,b,c   Lapérine, Olivier ^a,b,c   Guyomarch, Béatrice ^c,d   Merlini, Thierry ^a,b,c   Chatelais, Mathias ^a,b   Guilbaud, Florian ^a,b,c   Brennan, Meadhbh Áine ^a,b   Charrier, Céline ^a,b   Heymann, Dominique ^a,b,c   Gouëffic, Yann ^c,d   Heymann, Marie Franҫoise ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d L INSTITUT DU THORAX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; OSTEOPROTEGERIN; CD146 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; ASYMPTOMATIC DISEASE; BLOOD VESSEL CALCIFICATION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINERALIZATION; OSTEOBLAST; OSTEOCLAST; OSTEOID METAPLASIA; PERICYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; ATHEROSCLEROTIC PLAQUE; BLOOD; CAROTID STENOSIS; CYTOLOGY; METABOLISM; METAPLASIA; PATHOLOGY;

ANTIGENS, CD146; CAROTID STENOSIS; CELL DIFFERENTIATION; HUMANS; METAPLASIA; OSTEOBLASTS; OSTEOPROTEGERIN; PERICYTES; PLAQUE, ATHEROSCLEROTIC; RANK LIGAND; VASCULAR CALCIFICATION;

EID: 84907909069     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107642     Document Type: Article

References (40)

1. Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, et al. (2009) Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 5: 185-197.
2. Hoshino T, Chow LA, Hsu JJ, Perlowski AA, Abedin M, et al. (2009) Mechanical stress analysis of a rigid inclusion in distensible material: a model of atherosclerotic calcification and plaque vulnerability. Am J Physiol Heart Circ Physiol 297: H802-810.
3. Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, et al. (2002) Bone formation in carotid plaques: a clinicopathological study. Stroke 33: 1214-1219.
4. Qiao JH, Mertens RB, Fishbein MC, Geller SA (2003) Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: morphologic evidence of enchondral ossification. Hum Pathol 34: 402-407.
5. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, et al. (2009) RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104: 1041-1048.
6. Bunting CH (1906) The Formation of True Bone with Cellular (Red) Marrow in a Sclerotic Aorta. J Exp Med 8: 365-376.
7. Andreeva ER, Pugach IM, Gordon D, Orekhov AN (1998) Continuous subendothelial network formed by pericyte-like cells in human vascular bed. Tissue Cell 30: 127-135.
8. Collett GD, Canfield AE (2005) Angiogenesis and pericytes in the initiation of ectopic calcification. Circ Res 96: 930-938.
9. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, et al. (1993) Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91: 1800-1809.
10. Oksala N, Levula M, Pelto-Huikko M, Kytomaki L, Soini JT, et al. (2010) Carbonic anhydrases II and XII are up-regulated in osteoclast-like cells in advanced human atherosclerotic plaques-Tampere Vascular Study. Ann Med 42: 360-370.
11. Collin-Osdoby P (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95: 1046-1057.
12. Wong KK, Thavornpattanapong P, Cheung SC, Sun Z, Tu J (2012) Effect of calcification on the mechanical stability of plaque based on a three-dimensional carotid bifurcation model. BMC Cardiovasc Disord 12: 7.
13. Heymann MF, Herisson F, Davaine JM, Charrier C, Battaglia S, et al. (2012) Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine 58: 300-306.
14. Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, et al. (2012) Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol 7: 965-973.
15. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, et al. (2007) Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 99: 513-518.
16. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, et al. (2008) Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51: 627-633.
17. Ziegler S, Kudlacek S, Luger A, Minar E (2005) Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182: 175-180.
18. Golledge J, McCann M, Mangan S, Lam A, Karan M (2004) Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35: 1636-1641.
19. Kadoglou NP, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE, et al. (2008) The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 47: 55-62.
20. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, et al. (1995) A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92: 1355-1374.
21. (1998) Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351: 1379-1387.
22. (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325: 445-453.
23. Rerkasem K, Rothwell PM (2009) Systematic review of the operative risks of carotid endarterectomy for recently symptomatic stenosis in relation to the timing of surgery. Stroke 40: e564-572.
24. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, et al. (2003) Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361: 107-116.
25. (1995) Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273: 1421-1428.
26. Herisson F, Heymann MF, Chetiveaux M, Charrier C, Battaglia S, et al. (2011) Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis 216: 348-354.
27. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, et al. (2010) Clinicalgrade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115: 1549-1553.
28. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, et al. (2004) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36: 57-66.
29. Duplomb L, Baud'huin M, Charrier C, Berreur M, Trichet V, et al. (2008) Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine 727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 149: 3688-3697.
30. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
31. Wong BR, Josien R, Lee SY, Sauter B, Li HL, et al. (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186: 2075-2080.
32. Maldonado N, Kelly-Arnold A, Vengrenyuk Y, Laudier D, Fallon JT, et al. (2012) A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. Am J Physiol Heart Circ Physiol 303: H619-628.
33. New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, et al. (2013) Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ Res 113: 72-77.
34. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, et al. (1998) osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268.
35. Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, et al. (2011) Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 42: 3022-3028.
36. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
37. Tang Z, Wang A, Yuan F, Yan Z, Liu B, et al. (2012) Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat Commun 3: 875.
38. Tintut Y, Patel J, Parhami F, Demer LL (2000) Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102: 2636-2642.
39. Covas DT, Panepucci RA, Fontes AM, Silva WA Jr., Orellana MD, et al. (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 36: 642-654.
40. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, et al. (2005) Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204: 714-723.